

BIODELIVERY SCIENCES INTERNATIONAL INC
 Form 4
 September 23, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Vasisht Niraj

2. Issuer Name and Ticker or Trading Symbol
 BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 09/21/2016

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 Chief Technology Officer

C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVENUE, SUITE 225

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

RALEIGH, NC 27612

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2016		A		4,661	A	\$ 0 (1)
Common Stock	09/21/2016		M(2)		27,666	A	\$ 0 (2)
Common Stock	09/21/2016		M(3)		16,667	A	\$ 0 (3)
Common Stock	09/21/2016		M(4)		24,980	A	\$ 0 (4)
	09/21/2016		M(5)		66,667	A	

Common Stock						\$ 0		
						<u>(5)</u>		
Common Stock	09/21/2016		S ⁽⁶⁾	40,000	D	\$ 2.39	169,061	D
						<u>(7)</u>		
Common Stock	09/23/2016		S ⁽⁸⁾	7,000	D	\$ 2.68	162,061	D
						<u>(9)</u>		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	\$ 0	09/21/2016		M ⁽²⁾	27,666	02/20/2016	09/21/2016	Common Stock	27,666
Restricted Stock Units	\$ 0	09/21/2016		M ⁽³⁾	16,667	01/30/2016	01/30/2017	Common Stock	16,667
Restricted Stock Units	\$ 0	09/21/2016		M ⁽⁴⁾	24,980	02/22/2016	02/22/2017	Common Stock	24,980
Restricted Stock Units	\$ 0	09/21/2016		M ⁽⁵⁾	66,667	02/23/2016	02/23/2018	Common Stock	66,667

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Vasisht Niraj
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVENUE, SUITE 225
RALEIGH, NC 27612

Chief
Technology
Officer

Signatures

/s/ Niraj Vasisht 09/23/2016

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted

(1) Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016.

The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting

(2) Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016.

The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the

(3) Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017.

The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the

(4) Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.

The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the

(5) Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.

(6) The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.

On September 21, 2016, the Reporting Person sold an aggregate of 40,000 shares of the Issuer's Common Stock at a weighted average

price of \$2.39 per share. The highest sale price for the Common Stock was \$2.45 per share and the lowest sale price was \$2.35 per share.

(7) The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(8) The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of RSUs.

On September 23, 2016, the Reporting Person sold an aggregate of 7,000 shares of the Issuer's Common Stock at a weighted average

price of \$2.68 per share. The highest sale price for the Common Stock was \$2.81 per share and the lowest sale price was \$2.58 per share.

(9) The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.